Skip to main content
    M

    Monte Rosa Therapeutics Inc (GLUE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.16
    -0.21 (-2.24%)

    Market Cap: $800.67M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Monte Rosa Therapeutics Inc (GLUE) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Monte Rosa Therapeutics are Rigel Pharmaceuticals (RIGL), Structure Therapeutics Inc. American Depositary Shares (GPCR) and Oric Pharmaceuticals (ORIC). By market cap, Monte Rosa Therapeutics ranks 10th of the 13 companies on this page; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the largest at $1.43B.

    Peer Comparison

    GLUE's revenue growth of 325.8% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Monte Rosa Therapeutics (GLUE)$800.67MN/A13.3x-186.2%N/A325.8%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Mineralys Therapeutics, Inc. Common Stock (MLYS)$1.36BN/AN/A0.0%-51.1%0.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Silence Therapeutics PLC (SLN)$1.23BN/A882.5x0.0%N/A197.2%0.00%
    Design Therapeutics Inc (DSGN)$670.46MN/AN/A0.0%N/A0.0%0.00%
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    Alpha Tau Medical Ltd (DRTS)$1.24BN/AN/A0.0%-176.9%0.0%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Surrozen Inc (SRZN)$602.54MN/A36.1x0.0%N/A408.6%0.00%
    Tourmaline Bio Inc. (TRML)$1.23BN/AN/A0.0%N/A0.0%0.00%
    Peer median$917.01M54.6x36.1x0.0%-52.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Monte Rosa Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Mineralys Therapeutics, Inc. Common Stock (MLYS)
    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular...
    MLYS competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Silence Therapeutics PLC (SLN)
    Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology...
    SLN competitors
    Design Therapeutics Inc (DSGN)
    Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions.
    DSGN competitors
    Prime Medicine, Inc. Common Stock (PRME)
    Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology...
    PRME competitors
    Alpha Tau Medical Ltd (DRTS)
    Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development...
    DRTS competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    Surrozen Inc (SRZN)
    Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform...
    SRZN competitors
    Tourmaline Bio Inc. (TRML)
    Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions...

    Frequently Asked Questions About GLUE

    Who are Monte Rosa Therapeutics' main competitors?

    The companies most similar to Monte Rosa Therapeutics include Rigel Pharmaceuticals (RIGL), Structure Therapeutics Inc. American Depositary Shares (GPCR), Oric Pharmaceuticals (ORIC), Mineralys Therapeutics, Inc. Common Stock (MLYS) and Theravance Biopharma (TBPH), listed from the closest match.

    Who is Monte Rosa Therapeutics' biggest competitor?

    Structure Therapeutics Inc. American Depositary Shares (GPCR) is the largest of the similar companies at $1.43B; Rigel Pharmaceuticals (RIGL) is the closest match by business profile, size, sector and industry.

    How does GLUE stock compare with its competitors?

    GLUE's P/S is 13.3x against a peer median of 36.1x; its net margin is -186.2% against a peer median of 0.0%.

    Which of Monte Rosa Therapeutics' competitors pays a higher dividend?

    Monte Rosa Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Monte Rosa Therapeutics bigger than its competitors?

    No. Monte Rosa Therapeutics is 10th by market cap among the 13 companies on this page; the largest is Structure Therapeutics Inc. American Depositary Shares (GPCR) at $1.43B.